Semaglutide was a top-selling drug in 2023, and its popularity only ... While this drug can be expensive, Novo Nordisk offers a savings card for those with commercial or private insurance who ...

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Half of the participants were given semaglutide, the active ingredient in weight loss drugs, for nine weeks. The others received a placebo. At the end of the research period, both groups were ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current ...

An "exciting" new study has found that Semaglutide, the active ingredient of Wegovy and Ozempic, could help people to reduce their alcohol intake. The drugs were originally developed to treat type ...